Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Phase 2 Trial Using Talampanel in Patients With Recurrent High Grade Gliomas

A Phase II Trial of Talampanel in Patients With Recurrent High-Grade Gliomas.

To analyze the effect of Talampanel on progression free survival in patients with recurrent high grade gliomas.

Studieoversikt

Detaljert beskrivelse

To determine the efficacy of Talampanel in patients with recurrent malignant glioma as measured by 6-month progression survival, as well as to obtain preliminary information regarding the spectrum of toxicities of the drug among this patient population.

Studietype

Intervensjonell

Registrering (Faktiske)

30

Fase

  • Fase 2

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion

  1. Patients with histologically proven intracranial malignant glioma will be eligible for this protocol. Malignant glioma include glioblastoma multiforme (GBM), anaplastic astrocytoma (AA), anaplastic oligodendroglioma (AO), anaplastic mixed oligoastrocytoma (AMO), or malignant astrocytoma NOS (not otherwise specified).
  2. Patients must have unequivocal evidence for tumor progression by MRI or CT scan. This scan should be performed within 14 days prior to registration and on a steroid dosage that has been stable for at least 5 days.
  3. Patients having undergone recent resection of recurrent or progressive tumor will be eligible as long as all of the following conditions apply:

    1. They have recovered from the effects of surgery.
    2. Residual disease following resection of recurrent tumor is not mandated for eligibility into the study. To best assess the extent of residual disease post-operatively, a CT/ MRI should be done:

      • no later than 96 hours in the immediate post-operative period or
      • at least 4 weeks post-operatively, and
      • within 14 days of registration, and
      • on a steroid dosage that has been stable for at least 5 days.
  4. If the 96-hour scan is more than 21 days before registration, the scan needs to be repeated.
  5. Patients must have failed prior radiation therapy and must have an interval of greater than or equal to 4 weeks from the completion of radiation therapy to study entry.
  6. All patients must sign an informed consent indicating that they are aware of the investigational nature of this study.
  7. Patients must be > 18 years old, and with a life expectancy > 8 weeks.
  8. Patients must have a Karnofsky performance status of > 60.
  9. Patients must have recovered from the toxic effects of prior therapy: 4 weeks from any investigational agent, 4 weeks from prior cytotoxic therapy, two weeks from vincristine, 6 weeks from nitrosoureas, 3 weeks from procarbazine administration, and 1 week for non-cytotoxic agents, e.g., interferon, tamoxifen, thalidomide, cis-retinoic acid, etc. (radiosensitizer does not count).
  10. Patients must have adequate bone marrow function (ANC > 1,200/mm3, platelet count of > 100,000/mm3, and hemoglobin > 10 gm/dl), adequate liver function (SGOT and bilirubin < 2 times ULN), and adequate renal function (serum creatinine < 1.5 mg/dL otherwise a measured 24-hour creatinine clearance > 60 cc/min) before starting therapy. These tests must be performed within 14 days prior to registration.
  11. Patients must not have any significant medical illnesses that in the investigator's opinion cannot be adequately controlled with appropriate therapy or would compromise the patients' ability to tolerate this therapy.
  12. This study was designed to include women and minorities, but was not designed to measure differences of intervention effects.
  13. Patients must not have active infection requiring IV antibiotics.
  14. Patients must not be pregnant or nursing, and all patients (both men and women) must be willing to practice birth control during and for 2 months after treatment with Talampanel. Women of childbearing potential (WCBP) must have a negative serum or urine pregnancy test. In addition, sexually active WCBP must agree to use adequate contraceptive methods (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner).

Exclusion Criteria

  1. Patients who, in the view of the treating physician, have significant active cardiac, hepatic, renal, or psychiatric diseases are ineligible that would significantly increase the risk of using talampanel.
  2. No concurrent use of other standard chemotherapeutics or investigative agents.
  3. Patients known to have an active, life-threatening malignancy.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Intervensjonsmodell: Parallell tildeling

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: 1
Valproic: 10mg TID week 1, 25mg TID week 2, 35mg week 3
10mg, 25 mg, 35 mg, 50 mg, 75mg TID for 3 weeks
Eksperimentell: 2
Non-enzyme-inducing anti-epileptic drugs: 25mg TID week 1, 35mg week 2, 50mg week 3
10mg, 25 mg, 35 mg, 50 mg, 75mg TID for 3 weeks
Eksperimentell: 3
Enzyme-inducing anti-epileptic drugs: 35mg TID week 1, 505mg week 2, 75mg week 3
10mg, 25 mg, 35 mg, 50 mg, 75mg TID for 3 weeks

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart

1. juli 2003

Primær fullføring (Faktiske)

1. januar 2006

Studiet fullført (Faktiske)

1. april 2006

Datoer for studieregistrering

Først innsendt

6. juni 2003

Først innsendt som oppfylte QC-kriteriene

11. juni 2003

Først lagt ut (Anslag)

12. juni 2003

Oppdateringer av studieposter

Sist oppdatering lagt ut (Anslag)

23. mai 2011

Siste oppdatering sendt inn som oppfylte QC-kriteriene

20. mai 2011

Sist bekreftet

1. mai 2011

Mer informasjon

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere